

NUTRACEUTICALS IN THE PREVENTION AND TREATMENT OF
CARDIOVASCULAR DISEASES (CVDs)Dr. K. Sobhan Babu, Dr. J. N. Suresh Kumar, A. Anitha, B. Tirumala Rao, *B. Manasa, U. Bhavani and
J. Haveela

India.



*Corresponding Author: B. Manasa

India.

Article Received on 21/07/2024

Article Revised on 11/08/2024

Article Accepted on 01/09/2024

ABSTRACT

Encyclopaedically, cardiovascular conditions (CVDs) constitute the leading cause of death and disability. While nonpharmacological measures, primarily life variations, are the foundation of the original remedial approach to ameliorate the primary cardiovascular (CV) threat factors, adherence to recommendations regarding nutrients and/or bioactive composites of factory or microbial origin with potentially healthy goods has come wide. Unfortunately, because there have not been enough well- controlled intervention trials conducted on any of the nutraceuticals, at least, the scientific substantiation about the implicit advantages of using them remains equivocal. The scientific data from controlled intervention studies regarding the impact of some nutraceuticals on the primary cardiovascular threat factors — body weight, blood pressure, blood glucose — similar as fibre, phytosterols, soy products, red incentive rice, polyphenols, and berberine.^[1]

KEYWORDS: CVDs, nutraceuticals, hypertension, atherosclerosis.

INTRODUCTION

Cardiovascular complaint (CVD) is veritably common; in fact, utmost persons over sixty will have some kind of CVD. An estimated 17.3 million deaths encyclopaedically are attributed to CVD each time, according to data from 2012 and 2013.^[2] Though salutary factors haven't entered as important attention as the classic cardiovascular threat factors(Table 1), they're nevertheless significant in the pathophysiology of CVD and can impact CVD threat factors similar blood pressure and dyslipidaemia.^[3]

Table 1: Cardiovascular risk factors.

Category	Examples
Nonmodifiable risk Factors	Advancing age Male gender Family history
Metabolic risk factors	Hypertension Hyperlipidaemia Diabetes syndrome Obesity/overweight
Lifestyle risk factors	Diet Smoking Physical activity

The influence of salutary factors has been considerably studied through large-scale longitudinal cohort studies in which birth salutary consumption was linked to

cardiovascular issues, or by lowering the volume of specific food factors known to raise threat, similar as impregnated fats or sodium.^[3]

In India, CVD

One of the leading causes of death in India for individualities of all periods is CVD. Fat kiddies in India between the periods of 5 and 17 are more likely to have high blood pressure or inordinate cholesterol input, which raises their threat for cardiovascular conditions (CVDs) indeed though the threat of CVDs increases with age due to changes in life. roughly 30 million heart cases live in India now, and over 2,000 000 open heart procedures are performed there annually by cardiac institutions.^[2]

Nutraceuticals

Stephen DeFelice, the author and head of the Foundation for Innovation in Medicine, chased the word "nutraceuticals" in 1989. A " food, or corridor of a food, that give medical or health benefits, including the forestallment and treatment of complaint".^[4] Indeed, the name nutraceuticals was chased from the words " nutrition" and " pharmaceutical," primarily to encourage clinical exploration and trials targeted at determining the true health goods of these composites. Still, the word has been extensively used in marketing and still lacks a clear nonsupervisory description.^[5] Nutraceuticals have come an essential part of our diet because of their preventative

and remedial parcels against a variety of physiological problems (e.g., CVD, osteoarthritis, cancer, hypoglycaemia).^[2]

According to the Nutrition Business Journal, anything that's used primarily or especially for health purposes is appertained to as a nutraceuticals.^[6]

Nutraceutical factor

An existent's interest and/ or background will determine which organisational structure is stylish for nutraceuticals. Cardiologists, for case, might be particularly interested in nutraceutical constituents linked to lowering heart complaint threat factors. More specifically, they might be interested in medicines that are said to have a salutary effect on high blood pressure, high cholesterol, and platelet- or free revolutionary-dependent thrombotic exertion. It would be veritably intriguing to look at nutraceutical factors including grape flavonoids, phytosterols, quercetin, and n- 3 adipose acids.^[6]

Nutraceuticals in Hypertension

Hypertension is a major threat factor for CVDs and the leading cause of adding death rates in industrialised countries.^[7] Essential, primary, or idiopathic hypertension is responsible for 95 of all hypertension cases, which are characterised as high blood pressure with comorbidities similar as renal or vascular complaint, or renal failure. Hypertension causes 45 of heart attacks and 51 of strokes, as well as 9.4 million CVD- related deaths encyclopaedically.^[8]

Cases with hypertension have reduced antioxidant defence mechanisms, both endogenous and exogenous. Likewise, hypertension individualities have increased oxidative stress, with further ROS generated and a larger than normal response to oxidative stress.^[9] Because they include antioxidant nutrients like ascorbic acid(vitamin C), a number of foods are of interest and have been examined in light of the epidemiological increase of habitual non-communicable conditions like diabetes mellitus and cardiovascular events.^[8]

Vitamin C

Strong water-answerable antioxidant vitamin C reduces endothelial dysfunction, stimulates the product of diuresis, and recycles vitamin E.^[9] Vitamin C's potent antioxidant parcels work to lower the attention of towel oxygen species, which in the case of atherosclerosis helps to avoid endothelial dysfunction, circumscribe the proliferation of vascular smooth muscle, and lower oxidised low- viscosity lipoprotein cholesterol.^[3] With varying degrees of success, several studies have examined the effect of vitamin C, both salutary and supplement, in CVD.^[3] Fruits, vegetables, vitamin supplements, energy drinks, set breakfasts, and nutritive cereals are common sources of vitamin C, also known as ascorbic acid.^[10] According to published clinical trials, 250 mg doubly daily will lower blood pressure by about

7/4 mmHg, ameliorate arterial compliance, ameliorate endothelial function, reduce serum aldehydes, increase the efficacy of amlodipine, drop the AT 1 receptor's list affinity for angiotensin II, and enhance the antihypertensive goods of specifics in the senior with refractory hypertension.^[11]

Resveratrol

Resveratrol, a naturally being phenolic trihydroxystilbene (3, 4, 5- trihydroxy- trans- stilbene)(RESV), is a potent antioxidant set up in high attention in grape skin.^[7, 12] Individualities can admit modest quantities of resveratrol from foods similar as peanuts, grapes, and berries.^[13] RESV is hypothesised to help lower blood pressure when combined with normal antihypertensive drug by boosting the product of nitric oxide (NO), an endogenous and strong vasodilator. NO is created in the endothelium that lines blood highways, where it facilitates vasodilation by cranking an enzyme called guanylate cyclase (GC). It also commences a signalling waterfall that relaxes the smooth muscle and produces vasodilation. Vasodilation reduces supplemental resistance, which directly impacts arterial pressure and lowers BP.^[14]

Garlic

One of the most frequently used herbal remedies in Australia and the US is garlic (*Allium sativum* L.), which has been used to promote" cardiovascular health".^[15] Garlic or its medications contain hundreds of composites. The bioactive factors of whole, undamaged garlic that contain introductory sulphur include alliin and gamma- glutamyl- S- alk(en) yl- L- cysteines and S- alk(en) yl- L- cysteine sulfoxides.^[16] Supplementing with garlic has demonstrated implicit in the operation of unbridled hypertension, reducing blood pressure (BP) by around 10 mmHg systolic and 8 mmHg diastolic, which is similar to conventional BP drug.^[17] Raw garlic and medications made from it have lipid- lowering, antiatherosclerotic, antihypertensive, and other cardiovascular-defensive parcels. Garlic works biochemically to lower blood pressure by blocking the exertion of the angiotensin- converting enzyme, which lowers the product of vasoconstrictor prostanoids.^[18] Studies have demonstrated that garlic increases the conflation of NO and H₂S, two gasotransmitters that beget vasorelaxation.^[19]

Lycopene

Tomatoes, watermelon, pink grape fruit, papaya, apricots, and guava all contain lycopene, a carotenoid. The primary sources of lycopene in the diet are tomatoes and tomato- grounded products.^[8,20] Lycopene can quench free revolutionaries due to its strong antioxidant parcels, which may ameliorate vascular function and minimise cardiovascular problems.^[21] Lycopene is the most effective single oxygen and free radical scavenger among 600 naturally being carotenoids, thanks to its extended carbon chain and conjugated double bonds.^[22] Several trials set up that at least four weeks of regular

oral supplementation with excerpt or tomato juice reduced blood pressure.^[23] Several meta- analyses set up that lycopene supplementation significantly dropped systolic blood pressure(SBP) but not diastolic blood pressure(DBP) when compared to placebo(chengt al., 2017; Li and Xu, 2013).^[24]

Nutraceuticals in Atherosclerosis

The term atherosclerosis comes from Greek, which means thickening of the intimal layers of the arteries and fat accumulation.^[25] The most common kind of CVD is atherosclerosis, also known as coronary artery disease (CAD), which is characterised by cholesterol accumulation and inflammation of the major arteries.^[26] Atherosclerosis alone is infrequently murderous; it is thrombosis, which is triggered by a ruptured or eroding atherosclerotic plaque, that causes life-hanging clinical events similar as stroke and myocardial infarction (MI).^[27] Given the rising frequency of rotundity and diabetes in developing nations, the global prevalence of CVD is anticipated to rise, assessing a bigger cost burden on global health-care systems.^[28]

The steps of Atherosclerosis

Atherosclerosis is a multifaceted, intricate, and multistep chronic inflammatory disease that is marked by the gradual build-up of fibrous plaques that are filled with fat inside the arterial wall.^[29] The growth of plaque and several stages of inflammation associated with atherosclerosis are outlined below.

1. Fatty streak development

This can begin as beforehand as the 20s. This is where LDLs enter the middle layer of the plaque during its initial development, and begin to accumulate when their volume in blood levels rise and then oxidise to become pro-inflammatory cells. Because of this figure-up, the inflammatory intercessors released and activate VSMC that draws neutrophils, mast cells, lymphocytes, monocytes, collagen, and proteoglycans. At first, monocytes grow into foam cells through development of macrophages. This accumulation lipid is regarded as the initial stage, and treatment options depend on the quantity of fat build-up.

2. Formation of fibro atheroma

It is noted in late teenagers. This stage involves the foam cells and the inflammatory cells, which play an important part in the development of atheroma. Extracellularly buried proteoglycans, increases the lipid binding capability. During the procedure, many cells may die. These dead cells increase the inflammation. The dead cells are accumulated and are covered by lipid-rich core, which occupies roughly 50% of arteries diameter resulting in an impediment.

3. Thin-cap fibroatheroma and rupture

These are generally encountered in individuals over 50 years old. A thin cap forms around the plaque. In some locations, the cap becomes thin, may burst, causing

thrombogenesis, which is a life hanging threat. The ruptured caps can mend and become involved again the accumulation of collagen leads to the elaboration of atheromatous plaque.^[30]

4. Atherosclerotic plaque development

The rudiments of atherosclerotic plaque are listed below.

Vascular epithelium: The vascular epithelium interacts with the macromolecules and blood components to ameliorate the protein transport in plasma.

Arterial smooth muscle: The conservation of vascular repair and metabolism of blood products including lipids, as well as the production of numerous cytokines, is vital in the management of vascular wall tonus.

Lymphocytes: They may engage in immune reactions. Plaque's core consists of cell lesions, foam cells, calcium, cholesterol esters, and a mass of adipose substances. Lipid nucleus is pale yellow mass whose colour is caused by carotenoid pigments.^[25]

Natural products known as nutraceuticals are one of the eventuality remedy pathway being delved for the forestallment of atherosclerosis. They're hypothesised to have anti-inflammatory characteristics.^[28] Nutraceuticals fall into two orders(I) salutary supplements, which are goods meant to be taken in addition to a regular diet and that include one or further salutary factors with established nutritive benefits (similar as vitamins, minerals, sauces or active chemicals set up in sauces); and (II) functional refections. When consumed as part of a regular diet, they include whole foods as well as "fortified, amended, or enhanced" foods that have been supplemented with known biologically active substances that offer physiological benefits and are meant to lower the threat of developing habitual conditions in addition to macro and micronutrients. Multitudinous nutraceutical classes have demonstrated implicit benefits in the operation of CVDs and atherosclerosis; the bones for which there's significant substantiation of atherosclerosis protection are included below.^[30]

Virgin olive oil (VOO)

VOO is the juice from the initial pressing of Olea europea fruit. VOO is designated for products with acidity levels lower than 0.8%, peroxide contents less than 20 meq O₂/kg, and organoleptic attributes advanced than 6.5 as verified by expert tasters. The two fragments that make up VOO are saponifiable and non-saponifiable. Triglycerides represent 98.5-99.5% of the oil and are primarily responsible for esterifying oleic acid, with small quantities of other fatty acids are also esterified.^[31] Polyphenols found in olive oil play a significant part in the Mediterranean diet. It has been demonstrated that eating a diet high in polyphenols increases the bioavailability of nitric oxide (NO) and reduces inflammation and oxidative stress. Extra virgin olive oil (OO) has a significant antioxidant effect on

humans, as substantiated by recent randomised trials.^[32] Monosaturated oleic acid, which makes up 75% of the fatty acids in olive oil, prevents endothelial dysfunction and lessens the apoptosis that TNF- α -induced VSMCs undergo. Additionally, olive oil contains a variety of phenolic compounds, including hydroxytyrosol, oleocanthal, oleuropein, lignans, and pinoreosinol. Several studies in the field of epidemiology, clinical practice, and trial have been demonstrated the benefits of these olive derivatives in CVDs.^[30] Numerous studies conducted in vivo and in vitro have estimated hydroxytyrosol's potential utility as a nutraceutical for atherosclerosis. When hydroxytyrosol and pro-inflammatory cytokines were co-incubated in vitro with HUVEC, the expression of cell surface adhesion molecules including VCAM-1 and ICAM-1 was significantly lower than when the cytokines were incubated alone. Moreover, it has been demonstrated that hydroxytyrosol inhibits the synthesis of numerous pro-inflammatory markers in primary human monocyte cultures. A study conducted on mice using thirty-two Wistar rats fed a diet high in olive oil for six weeks showed that an olive oil loaded in phenol could considerably raise plasma HDL levels. The non-enriched virgin olive oil did not significantly change HDL levels, according to the same study, suggesting that the olive oil's cardioprotective properties.^[25]

Vitamin-D

A fat-soluble vitamin, vitamin D is essential for several physiological functions in addition to its well-known role in bone and calcium metabolism. Maintaining the body's appropriate amounts of vitamin D requires knowledge of its sources. Sunlight exposure and food sources are two ways to obtain vitamin D. Fish high in fat, such as tuna, salmon, and mackerel, as well as dairy products fortified with calcium, such as milk, yoghurt, and cheese, are dietary sources of vitamin D. These food sources contain cholecalciferol, or vitamin D3, which is the form of the vitamin that the body uses most readily.^[33] By reducing the expression of TNF α , IL-6, IL-1, and IL-8 in isolated blood monocytes, vitamin D signalling may modify the inflammatory response and impact the pathogenesis of atherosclerosis. Reduced production of the acute-phase inflammatory C-reactive protein (CRP) results from suppression of IL-6. Serum values of CRP are predictive of cardiovascular events and are linked to atherosclerosis. It has been demonstrated that a deficit in vitamin D accelerates the development of coronary artery disease in pigs by increasing the activation of nuclear factor- κ B (NF- κ B), which underlines vitamin D's anti-inflammatory properties.^[34]

Coca

In the last ten years, studies on nutrition have connected brief exposure to cocoa that is high in flavanols to changes in antioxidant defence and vascular health. Long-term ingestion has been shown in animal models to reverse dietary endotoxemia and inflammation brought on by high-fat feeding. Improved flow-mediated dilatation, higher vascular compliance, increased high-

density lipoprotein cholesterol (HDL-c), and decreased monocyte adhesion molecule expression (CD11b and CD62L) are the most common outcomes linked to short-term natural cocoa intake. Reduced monocyte adhesion and increased HDL-c may indicate a general decline in the ability to generate foam cells, the initial stage of atherosclerosis.^[35] Chocolates, especially dark chocolates, include cocoa, which is high in flavonoids linked to cardiovascular health benefits. These advantages are associated with antioxidant activity, enhanced insulin sensitivity, reduced platelet aggregation, decreased expression of adhesion molecules, and nitric oxide activation—a strong vasodilator that lowers blood pressure.^[36] Through the inhibition of 5-lipoxygenase, cocoa modulates the endothelial cell eicosanoid system pathway, increasing the vasodilatory prostacyclin and decreasing leukotrienes. A measure of the proinflammatory/anti-inflammatory eicosanoid balance, the plasma leukotriene/prostacyclin ratio, has decreased, suggesting that cocoa may have an anti-inflammatory effect. Cocoa's anti-inflammatory properties may contribute to its favourable effects on vascular function, as inflammation is linked to increased stiffness of the aorta.^[37]

REFERENCES

1. Rivellese, A.A., Ciciola, P., Costabile, G. *et al.* The Possible Role of Nutraceuticals in the Prevention of Cardiovascular Disease. *High Blood Press Cardiovasc Prev*, 2019; **26**: 101–111. <https://doi.org/10.1007/s40292-019-00309-5>
2. Sosnowska B, Penson P, Banach M. The role of nutraceuticals in the prevention of cardiovascular disease. *Cardiovasc Diagn Ther*, 2017 Apr; **7** (Suppl 1): S21–S31. doi: 10.21037/cdt.2017.03.20. PMID: 28529919; PMCID: PMC5418215.
3. Alissa, Eman M., Ferns, Gordon A., Functional Foods and Nutraceuticals in the Primary Prevention of Cardiovascular Diseases, *Journal of Nutrition and Metabolism*, 2012; 569486: 16 pages, 2012. <https://doi.org/10.1155/2012/569486>
4. Zuchi, C., Ambrosio, G., Lüscher, T.F. and Landmesser, U. (2010), Nutraceuticals in Cardiovascular Prevention: Lessons from Studies on Endothelial Function. *Cardiovascular Therapeutics*, **28**: 187–201. <https://doi.org/10.1111/j.1755-5922.2010.00165.x>
5. Spoorthi, B. C., et al. "Nutraceuticals: Potential therapeutic agents for the treatment and prevention of cardiovascular diseases." *Journal of Pharmacy Research*, 2018; **12**: 231.
6. Keservani, Raj K., Rajesh K. Kesharwani, Narendra Vyas, Sarang Jain, Ramsaneh Raghuvanshi, and Anil K. Sharma. "Nutraceutical and functional food as future food: A review." *Der Pharmacia Lettre*, 2010; **2**: 1: 106–116.
7. Carrizzo, A., Izzo, C., Forte, M., Sommella, E., Di Pietro, P., Venturini, E., ... & Vecchione, C. (2020). A novel promising frontier for human health: The

- beneficial effects of nutraceuticals in cardiovascular diseases. *International Journal of Molecular Sciences*, 2020; 21(22): 8706.
8. Alves, Quiara Lovatti, Samuel Barbosa Camargo, and Darizy Flavia Silva. "Role of nutraceuticals in the prevention and treatment of hypertension and cardiovascular diseases." *J Hypertens Manag*, 2019; 5.1: 1-10.
 9. Houston, M.C., 2010. Nutrition and nutraceutical supplements in the treatment of hypertension. *Expert review of cardiovascular therapy*, 8(6): 821-833.
 10. Guan, Yuanyuan, Pengju Dai, and Hongwu Wang. "Effects of vitamin C supplementation on essential hypertension: A systematic review and meta-analysis." *Medicine*, 2020; 99.8: e19274.
 11. Houston, Mark C. "The role of cellular micronutrient analysis, nutraceuticals, vitamins, antioxidants and minerals in the prevention and treatment of hypertension and cardiovascular disease." *Therapeutic Advances in Cardiovascular Disease*, 2010; 4.3: 165-183.
 12. NADERALI, E. K., SMITH, S. L., DOYLE, P. J., & Williams, G. (2001). The mechanism of resveratrol-induced vasorelaxation differs in the mesenteric resistance arteries of lean and obese rats. *Clinical Science*, 100(1): 55-60.
 13. Dyck, G. J., Raj, P., Zieroth, S., Dyck, J. R., & Ezekowitz, J. A. (2019). The effects of resveratrol in patients with cardiovascular disease and heart failure: a narrative review. *International journal of molecular sciences*, 20(4): 904.
 14. Theodotou, M., Fokianos, K., Mouzouridou, A., Konstantinou, C., Aristotelous, A., Prodromou, D., & Chrysikou, A. (2017). The effect of resveratrol on hypertension: A clinical trial. *Experimental and Therapeutic Medicine*, 13(1): 295-301.
 15. Chan, W. J. J., McLachlan, A. J., Luca, E. J., & Harnett, J. E. (2020). Garlic (*Allium sativum* L.) in the management of hypertension and dyslipidemia—A systematic review. *Journal of Herbal Medicine*, 19: 100292.
 16. Ugwu, C. E., & Suru, S. M. (2016). The functional role of garlic and bioactive components in cardiovascular and cerebrovascular health: what we do know. *Journal of Biosciences and Medicines*, 4(10): 28-42.
 17. Ried, K., & Fakler, P. (2014). Potential of garlic (*Allium sativum*) in lowering high blood pressure: mechanisms of action and clinical relevance. *Integrated blood pressure control*, 71-82.
 18. Xiong, X. J., Wang, P. Q., Li, S. J., Li, X. K., Zhang, Y. Q., & Wang, J. (2015). Garlic for hypertension: A systematic review and meta-analysis of randomized controlled trials. *Phytomedicine*, 22(3): 352-361.
 19. Ried, K. (2016). Garlic lowers blood pressure in hypertensive individuals, regulates serum cholesterol, and stimulates immunity: an updated meta-analysis and review. *The Journal of nutrition*, 146(2): 389S-396S.
 20. Przybylska, S., & Tokarczyk, G. (2022). Lycopene in the prevention of cardiovascular diseases. *International Journal of Molecular Sciences*, 23(4): 1957.
 21. Asbaghi, O., Nazarian, B., Naeini, F., Kaviani, M., Moradi, S., Askari, G., ... & Ashtary-Larky, D. (2022). Lycopene Supplementation and Blood Pressure: Systematic review and meta-analyses of randomized trials. *Journal of Herbal Medicine*, 31: 100521.
 22. Bin-Jumah, M. N., Nadeem, M. S., Gilani, S. J., Mubeen, B., Ullah, I., Alzarea, S. I., ... & Kazmi, I. (2022). Lycopene: a natural arsenal in the war against oxidative stress and cardiovascular diseases. *Antioxidants*, 11(2): 232.
 23. Li, X., & Xu, J. (2013). Lycopene supplement and blood pressure: an updated meta-analysis of intervention trials. *Nutrients*, 5(9): 3696-3712.
 24. Rattanavipanon, W., Nithiphongwarakul, C., Sirisuwansith, P., Chaivasothi, T., Thakkestian, A., Nathisuwan, S., & Pathomwichaiwat, T. (2021). Effect of tomato, lycopene and related products on blood pressure: A systematic review and network meta-analysis. *Phytomedicine*, 88: 153512.
 25. Rafieian-Kopaei, M., Setorki, M., Doudi, M., Baradaran, A., & Nasri, H. (2014). Atherosclerosis: process, indicators, risk factors and new hopes. *International journal of preventive medicine*, 5(8): 927.
 26. Björkegren, J. L., & Lusis, A. J. (2022). Atherosclerosis: recent developments. *Cell*, 185(10): 1630-1645.
 27. Falk, E. (2006). Pathogenesis of atherosclerosis. *Journal of the American College of cardiology*, 47(8S): C7-C12.
 28. Moss, J. W., & Ramji, D. P. (2016). Nutraceutical therapies for atherosclerosis. *Nature Reviews Cardiology*, 13(9): 513-532.
 29. Aquila, G., Marracino, L., Martino, V., Calabria, D., Campo, G., Caliceti, C., & Rizzo, P. (2019). The use of nutraceuticals to counteract atherosclerosis: the role of the notch pathway. *Oxidative medicine and cellular longevity*, 2019(1): 5470470.
 30. Reddy, M. S. (2020). Steps of atherosclerosis and its complication. *Journal of Medical Pharmaceutical and Allied Sciences*, 9(4): 2577-2579.
 31. Lou-Bonafonte, J. M., Arnal, C., Navarro, M. A., & Osada, J. (2012). Efficacy of bioactive compounds from extra virgin olive oil to modulate atherosclerosis development. *Molecular nutrition & food research*, 56(7): 1043-1057.
 32. Widmer, R. J., Freund, M. A., Flammer, A. J., Sexton, J., Lennon, R., Romani, A., ... & Lerman, A. (2013). Beneficial effects of polyphenol-rich olive oil in patients with early atherosclerosis. *European Journal of Nutrition*, 52: 1223-1231.
 33. Khanolkar, S., Hirani, S., Mishra, A., Vardhan, S., Hirani, S., Prasad, R., & Wanjari, M. (2023). Exploring the role of vitamin D in atherosclerosis

- and its impact on cardiovascular events: a comprehensive review. *Cureus*, 15(7).
34. Latic, N., & Erben, R. G. (2020). Vitamin D and cardiovascular disease, with emphasis on hypertension, atherosclerosis, and heart failure. *International journal of molecular sciences*, 21(18): 6483.
 35. McFarlin, B. K., Venable, A. S., Henning, A. L., Prado, E. A., Sampson, J. N. B., Vingren, J. L., & Hill, D. W. (2015). Natural cocoa consumption: Potential to reduce atherogenic factors?. *The Journal of nutritional biochemistry*, 26(6): 626-632.
 36. de Paula Silva, T., Silva, A. A., Toffolo, M. C. F., & de Aguiar, A. S. (2022). The action of phytochemicals present in cocoa in the prevention of vascular dysfunction and atherosclerosis. *Journal of clinical and translational research*, 8(6): 509.
 37. Páramo, J. A. (2008). A new favourable effect of cocoa on atherosclerosis?. *Cardiovascular research*, 79(1): 3-4.